/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Regeneron Pharmaceuticals has significantly underperformed the broader pharma space over the past year, yet analysts remain optimistic about the stock’s prospects.
Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET.
BROS. ADVISORS LP BAKER, a director at $BGNE ($BGNE), sold 916,964 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 9.5% of...
Xiaodong Wang, a director at $BGNE ($BGNE), sold 200 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.7% of their shares....
The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END
/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – The surge in...
Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.
The big pharma company's top drug is losing ground, but its dividend keeps rising.